Scientific publications for BioPredictive non-invasive diagnostics
Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.
79/433
Matches for
“HCC, hepatocellular carcinoma”
-
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.
…of HCC at 5 years. ### Lay Summary Hepatocellular carcinoma (HCC) is the…
-
External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B.
…repair (apolipoprotein A1, haptoglobin), hepatocellular carcinoma (HCC) risk factors (gender, age, gamma…
-
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis.
### Background No blood test has been shown to be effective in the…
-
Management of the patient with SVR. Review
…in rates of liver complications, hepatocellular carcinoma and mortality. Additional benefits include…
-
Personalized management of cirrhosis by non-invasive tests of liver fibrosis.
…In particular, their role in the selection of patients for hepatocellular carcinoma…
-
Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
…and alpha-fetoprotein (AFP), a hepatocellular carcinoma risk marker, pre- and post…
-
Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease.
…in patients with early stage hepatocellular carcinoma, but its specificity according to…
-
Comparison of acoustic radiation force impulse imaging with transient elastography for the detection of complications in patients with cirrhosis.
…The AUROC for the detection of hepatocellular carcinoma (HCC) was 0.54…
-
Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection
-
Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).
…8-5.7]), including hepatocellular carcinoma (HCC) in 21 (3.7% [1…
-
FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases.
-
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication
-
Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.
…cirrhosis, and 4 cases of hepatocellular carcinoma. In the population with type…
-
Prognostic value of the combined use of transient elastography and fibrotest in patients with chronic hepatitis B.
…LRE was defined as hepatic decompensation, hepatocellular carcinoma (HCC) or liver-related…
-
Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali.
### Background Hepatitis B (HB) infection is common in Mali. However, there is…
-
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
-
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.
-
Altered serum N-glycomics in chronic hepatitis B patients.
### Background We previously reported on serum N-glycans as markers for the…
-
Contribution of the ELFG test in algorithms of non-invasive markers towards the diagnosis of significant fibrosis in chronic hepatitis C.
### Background And Aims We aimed to determine the best algorithms for the…
-
Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection.
…as decompensated cirrhosis and hepatocellular carcinoma (HCC), without intervention. Due to the…
-
Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics.
…risk of complications (such as hepatocellular carcinoma) has increased considerably. Our clinical…
-
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.
-
Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males.
### Unlabelled Males have strikingly increased risk of advanced liver disease. However, the…
-
Is it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters?
…bleeding) or evolution toward hepatocellular carcinoma (HCC); 2) the presence of liver…
-
EASL Clinical Practice Guidelines: management of hepatitis C virus infection.
-
Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.
### Background And Aims Chronic hepatitis C (HCV) is a liver disease affecting…
-
Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B.
…and all five cases of hepatocellular carcinoma occurred in profiles C (n…
-
Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis.
### Background & Aims There is controversy about the performance of noninvasive tests such…
-
Prevalence of liver cirrhosis in individuals with hepatitis B virus infection in sub-Saharan Africa: Systematic review and meta-analysis. Review
### Background & Aims Chronic hepatitis B virus (HBV) infection accounts for 30%-50…
-
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication
-
Guidelines for the screening, care and treatment of persons with hepatitis C infection Key publication
-
The non-invasive assessment of hepatic fibrosis.
Hepatic disease accounts for approximately 2 million deaths/year worldwide. Liver fibrosis…
-
Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.
### Introduction Nonalcoholic fatty liver disease (NAFLD) is one of the most common…
-
Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.
### Background & Aims Therapeutic options for patients failing hepatitis C retreatment are limited…
-
HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
Acute hepatitis C virus infection remains a major health concern in human…
-
Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis.
Patients infected with hepatitis C virus (HCV) have differing levels of liver…
-
Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.
### Background & Aims Chronic hepatitis C is both a virologic and fibrotic disease…
-
Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.
### Introduction Long-term tenofovir disoproxil fumarate (TDF) use has been associated with…
-
Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B.
### Background And Aims Liver stiffness measurement (LSM) and FibroTest (FT) are frequently…
-
Hepatitis B: are non-invasive markers of liver fibrosis reliable?
Liver biopsy, which was traditionally considered to be the gold standard for…
-
Finasteride and methadone use and risk of advanced hepatitis C related liver disease.
### Aim We evaluated the association between two medications that alter bioavailable androgen…
-
Predictive value of biomarkers of hepatic fibrosis in adult Fontan patients.
### Background Hepatic fibrosis is highly prevalent in individuals with Fontan circulation. FibroSure…
-
Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.
### Background Direct antiviral agents (DAA) showed very good results in terms of…
-
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication
Chronic hepatitis C remains a significant medical and economic burden in Canada…
-
Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B.
### Background And Aims Diagnostic values of FibroTest (FT) for hepatic fibrosis have…
-
Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.
### Objective To determine practices among physicians in Canada for the assessment of…
-
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication
### Background No blood test has been shown to be effective in the…
-
Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.
### Background & Aims Coffee or caffeine has been proposed to protect against hepatic…
-
American Association for the Study of the Liver
-
Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis.
The limitations of liver biopsy (invasive procedure, sampling errors, inter-observer variability…
-
Noninvasive diagnosis in alcohol-related liver disease. Review
### Background Alcohol-related liver disease (ALD) represents a major cause of death…
-
Non-invasive Investigations for the Diagnosis of Fontan-Associated Liver Disease in Pediatric and Adult Fontan Patients.
…No cases of hepatocellular carcinoma were identified. Abnormalities suggestive of FALD occur…
-
Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C.
### Background Previous research has shown variation in the effects of patient factors…
-
EASL clinical practical guidelines: management of alcoholic liver disease.
-
Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.
### Background And Aim Mortality of alcohol-related liver disease (ArLD) is increasing…
-
Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores.
### Background/Aims To assess prospectively the accuracy of transient elastography (TE, FibroScan…
-
Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV.
### Background Medical comorbidities and functional status limitations are determinants of mortality in…
-
Noninvasive evaluation of NAFLD.
A common clinical concern in patients with NAFLD is whether they have…
-
Validation of Ten Noninvasive Diagnostic Models for Prediction of Liver Fibrosis in Patients with Chronic Hepatitis B.
### Background And Aims Noninvasive models have been developed for fibrosis assessment in…
-
An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. Key publication
### Background The combination of transaminases (ALT), biopsy, HBeAg and viral load have…
-
Liver fibrosis in adults with Fontan palliation: Do common screening studies predict disease severity?
-
The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.
### Background Nonalcoholic fatty liver disease (NAFLD) is common in bariatric surgery candidates…
-
Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.
### Background Excessive alcohol consumption may lead to the development of alcohol-related…
-
The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.
### Background Performance of non-invasive fibrosis biomarkers may be influenced by aetiology…
-
Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.
Patients with HIV have a proclivity to develop liver fibrosis, especially when…
-
Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review
Even though alcohol-related liver disease (ALD) is a major cause of…
-
Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).
…of all severe complications including hepatocellular carcinoma, hepatic insufficiency, and variceal bleeding…
-
FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication
FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients…
-
Non-invasive markers for hepatic fibrosis.
With great advancements in the therapeutic modalities used for the treatment of…
-
A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation.
### Background Chronic HCV is one of the major causes of morbidity and…
-
Discordance between liver biopsy and FibroTest in assessing liver fibrosis in chronic hepatitis B.
### Background And Aims The FibroTest (FT) demonstrated excellent diagnostic performance in the…
-
Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus.
…stiffness and the risk of hepatocellular carcinoma has been published. ### Aim To…
-
Hepatic and renal end-organ damage in the Fontan circulation: A report from the Australian and New Zealand Fontan Registry.
…no patient was diagnosed with hepatocellular carcinoma. FibroScan median kPa was ≥10…
-
Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.
### Objective Nonalcoholic steatohepatitis (NASH) has become a prominent liver disease in contemporary…
-
Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study.
### Background The efficacy of a maintenance therapy in non-responder patients with…
-
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.
### Background & Aims Nonalcoholic steatohepatitis (NASH) is a prevalent liver disease associated with…
-
Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease.
Alcoholic liver disease (ALD) consists of a broad spectrum of disorders, ranging…
-
Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.
### Background African Americans have lower reported likelihood of hepatitis C virus-related…
-
Ministère des Affaires Sociales et de la Santé Key publication
Showing the full result list. The page is server-rendered and not paginated.